AIDS Issues: Hearings Before the Subcommittee on Health and the Environment of the Committee on Energy and Commerce, House of Representatives, Ninety-ninth Congress, First Session, on Research and Treatment for Acquired Immune Deficiency Syndrome, July 22, 1985; Protection of Confidentiality of Records of Research Subjects and Blood Donors, July 29, 1985; Cost of AIDS Care and who is Going to Pay, November 1, 1985, Volume 4U.S. Government Printing Office, 1985 - 357 pages |
From inside the book
Results 1-5 of 31
Page 12
... Identification and purification of antigens to be used in HTLV - III vaccine development . ( NCI -- $ 150,000 ) Safety and antigenicity testing in humans of candidate AIDS vaccines . Outreach Activities ( NIAID -- $ 1,000,000 ) ...
... Identification and purification of antigens to be used in HTLV - III vaccine development . ( NCI -- $ 150,000 ) Safety and antigenicity testing in humans of candidate AIDS vaccines . Outreach Activities ( NIAID -- $ 1,000,000 ) ...
Page 19
... identifying the appropriate drugs and estab- lishing the appropriate dosage , additional studies are needed to select the optimal combinations of various agents in order to assure that the drugs chosen are not antagonistic . The ...
... identifying the appropriate drugs and estab- lishing the appropriate dosage , additional studies are needed to select the optimal combinations of various agents in order to assure that the drugs chosen are not antagonistic . The ...
Page 23
... identification of the disease , research was initiated by the PHS . Initially the major effort was by the PHS in- tramural research laboratories because of the ease logistically of mobilizing resources and changing research direction in ...
... identification of the disease , research was initiated by the PHS . Initially the major effort was by the PHS in- tramural research laboratories because of the ease logistically of mobilizing resources and changing research direction in ...
Page 26
... identifying the appropriate patients for study , the appropriate agents for study , and establishing the appropriate dosage , additional studies are needed to select the optimal combinations of various agents in order to assure that the ...
... identifying the appropriate patients for study , the appropriate agents for study , and establishing the appropriate dosage , additional studies are needed to select the optimal combinations of various agents in order to assure that the ...
Page 43
... identification of the disease , research was initiated by the PHS . Initially the major effort was by the PHS intramural research laboratories because of the ease logistically of mobilizing resources and changing research direction in ...
... identification of the disease , research was initiated by the PHS . Initially the major effort was by the PHS intramural research laboratories because of the ease logistically of mobilizing resources and changing research direction in ...
Other editions - View all
Common terms and phrases
additional AIDS epidemic AIDS patients AIDS victims AIDS virus American antibody test antiviral agents Association Belle Glade blood and plasma blood banks blood or plasma blood products Blue Cross cells Chairman clinical confidentiality cost coverage DANNEMEYER diagnosis disability disclosure donate blood drug eligible ELISA employers estimated evaluation facilities factor IX factor VIII Federal funding Glades General Hospital health insurance hemophilia hospital HTLV-III antibody HTLV-III virus immune globulin increased risk individuals infected Kaposi's sarcoma LEHNHARD lymphadenopathy Medicaid Medicare million NIELSON Office of Biologics patients with AIDS percent persons plasma plasma collection plasma derivatives plasmapheresis positive potential present problem procedures programs protect Public Health Service questions reactive retrovirus risk groups SCHEUER screening sexual Source Plasma specific studies Subcommittee suramin Syndrome AIDS test results therapy tion transfusion trials viral WACHS WAXMAN Western blot York City
Popular passages
Page 171 - Records of the identity, diagnosis, prognosis, or treatment of any patient which are maintained in connection with the performance of any drug abuse prevention function...
Page 171 - ... conducted, regulated, or directly or indirectly assisted by any department or agency of the United States shall, except as provided in subsection (c), be confidential and be disclosed only for the purposes and under the circumstances expressly authorized under subsection (b) of this section.
Page 166 - An IRB may waive the requirement for the investigator to obtain a signed consent form for some or all subjects if it finds either: (1) That the only record linking the subject and the research would be the consent document and the principal risk would be potential harm resulting from a breach of confidentiality. Each subject will be asked whether the subject wants documentation linking the subject with...
Page 159 - Consistent with the recommendations of the American Red Cross, the American Association of Blood Banks, the Council of Community Blood Centers, the...
Page 165 - A disclosure of appropriate alternative procedures or courses of treatment, if any, that might be advantageous to the subject; (5) A statement describing the extent, if any, to which confidentiality of records identifying the subject will be maintained...
Page 166 - When appropriate, the research plan makes adequate provision for monitoring the data collected to ensure the safety of subjects. (7) When appropriate, there are adequate provisions to protect the privacy of subjects and to maintain the confidentiality of data.
Page 155 - DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Rockville...
Page 178 - In addition, three major organizations dedicated to the development of high standards of donor protection and blood transfusion therapy — the American Association of Blood Banks, the American Red Cross, and the Council of Community Blood Centers...
Page 223 - The White House 1600 Pennsylvania Avenue NW Washington, DC 20500 Dear Mr. President: I am...
Page 150 - HTLV-III antibody should be offered to persons who may have been infected as a result of their contact with seropositive individuals (eg, sexual partners, persons with whom needles have been shared, infants born to seropositive mothers).